Clinical Chemistry, Vol 40, 385-388, Copyright © 1994 by American Association for Clinical Chemistry

Enzymatic diagnosis of aspartylglycosaminuria by fluorometric assay of glycosylasparaginase in serum, plasma, or lymphocytes

I Mononen, T Mononen, P Ylikangas, V Kaartinen and K Savolainen
Department of Clinical Chemistry, Kuopio University Hospital, Finland.

Serum, plasma, and lymphocytes from aspartylglycosaminuria (AGU) patients and carriers and from normal controls were incubated with a fluorescent glycosylasparaginase substrate, L-aspartic acid beta-(7- amido-4-methylcoumarin), and the release of 7-amino-4-methylcoumarin was measured fluorometrically after incubation for 1-4 h. The mean glycosylasparaginase (EC 3.5.1.26) activity in normal serum, plasma, and lymphocytes was 20.2 (SD 5.0) mU/L (n = 24), 17.5 (SD 5.0) mU/L (n = 24), and 242 (SD 108) mU/g protein (n = 17), respectively. The corresponding values in the Finnish AGU patients were 0.7 (SD 0.4) mU/L (n = 10), 0.3 (SD 0.3) mU/L (n = 10), and 6.0 (SD 4.6) mU/g protein (n = 7). No overlapping values were obtained between the AGU patients and the carriers in any of the samples, but the values between the carriers and controls were overlapping in 28 of 29 serum, 22 of 29 plasma, and 4 of 21 lymphocyte samples. Thus, the fluorometric glycosylasparaginase assay in various blood samples allows specific detection of the enzyme defect in AGU, but cannot be used for reliable detection of carriers of the disease.

The following articles in journals at HighWire Press have cited this article:

				M Arvio, K Laiho, M Kauppi, M Peippo, P Leino, H Kautiainen, O Kaipiainen-Seppanen, and I Mononen Carriers of the aspartylglucosaminuria genetic mutation and chronic arthritis Ann Rheum Dis, February 1, 2002; 61(2): 180 - 181. [Abstract] [Full Text] [PDF]